This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Look: A Review of FTX-6058 in treating sickle cell disease following the update from EHA

Ticker(s): FULC

Who's the expert?

Institution: UC Irvine

  • Clinical Professor, Medicine and Hematologist at UC Irvine.
  • Currently manages 60 patients with sickle cell disease.
  • Research interest in health outcomes for sickle cell disease; she specializes in benign hematology, including anemia, sickle cell disease, autoimmune diseases, clotting and blood disorders, and low platelets.

Interview Questions
Q1.

Roughly how many patients with sickle cell disease do you currently manage?

Added By: c_admin
Q2.

What were your thoughts on the initial data from the ongoing Phase 1b trial of FTX-6058?

Added By: c_admin
Q3.

On a scale from 1-10, 10 being extremely excited, where would you rate your level of excitement for FTX-6058?

Added By: c_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.